This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
WCET 2024
BCAN TT 2024
SNMMI 2024
ASCO 2024
AUA 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ESMO 2022
ESMO 2022 Testicular and Penile Cancer
ESMO 2022
Prostate Cancer
Bladder Cancer
Testicular and Penile Cancer
Press Releases
Kidney Cancer
ESMO 2022 Testicular and Penile Cancer
Viewing 41-60 of 11532 articles
BCANTT 2024: Bladder Cancer Care Implementation: NCCN Bladder Cancer Guidelines
BCANTT 2024: A Rapid Intro to Implementation Science
BCANTT 2024: Implementation of Smoking Cessation for Patients with Bladder Cancer
BCANTT 2024: Disrupting the Paradigm of First-line Therapy in Metastatic Urothelial Cancer
BCANTT 2024: Identifying Individual and Community-Level Drivers of Disparities in Bladder Cancer Clinical Trials Participation
AMA 2024: Updates on Public Health Related Policy Adopted at the AMA 2024 Annual Meeting
SNMMI 2024: Response Assessment in RPTs for Prostate Cancer: Everyone’s A Winner
AMA 2024: Updates on Legislation Related Policy Adopted at the AMA 2024 Annual Meeting
AMA 2024: Updates on Science and Technology Related Policy Adopted at the AMA 2024 Annual Meeting
AMA 2024: Updates on Medical Practice Related Policy Adopted at the AMA 2024 Annual Meeting
ASCO 2024: Validation of a Digital Pathology-Based Multimodal Artificial Intelligence Model in Oligometastatic Castration-Sensitive Prostate Cancer, Including in Patients from the STOMP and ORIOLE Phase II Randomized Clinical Trials
SNMMI 2024: Registrational Trials for PSMA PET
SNMMI 2024: Prognostic Value of Post-Therapy SPECT/CT Imaging in Patients Undergoing 177Lu-PSMA-617 Radioligand Therapy: Results from 3 Clinical Trials
SNMMI 2024: PSMA PET/CT Radiomics: Assessment of Adverse Pathological Risk and Proteomic Biomarker Correlations in Prostate Cancer
SNMMI 2024: Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177Lu PSMA Therapy: Comparison to Quantitative SUVmean and Patient Outcomes
SNMMI 2024: 18F-DCFPyL PET/MRI Radiomics for Intraprostatic Prostate Cancer Detection and Metastases Prediction Using Whole-Gland Segmentation
SNMMI 2024: Comparison of Post-Therapy 4 and 24-hour 177Lu-PSMA SPECT/CT and Pre-Therapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castrate-Resistant Prostate Cancer
SNMMI 2024: 68Ga-P16-093 Diagnostic Performance in Newly Diagnosed Prostate Cancer- Histopathologic Correlation
SNMMI 2024: Determining the Simplified Quantification Method of [18FAlF-P16-093 for Patients with Primary Prostate Cancer
SNMMI 2024: Eligibility for PSMA-RLT Based on Dual FDG/PSMA-PET: A Subanalysis of the 3TMPO Study
1
2
3
4
5
6
7
8
9
10
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free
